Press Release


EUROAPI sells Haverhill site to Particle Dynamics
as part of its FOCUS-27 transformation plan

Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase
agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating
its Haverhill manufacturing site, with a simultaneous closing to Particle Dynamics - a
global leader in particle processing, delivery technologies, and finished dose
manufacturing for the nutraceutical, consumer health, and pharmaceutical sectors.
“The divestment of Haverhill is a key step toward optimizing our industrial footprint and
advancing our FOCUS-27 transformation plan. This transaction strengthens our
efficiency and focus on our strategic network, reinforcing our commitment to
execution,” said David Seignolle, Chief Executive Officer of EUROAPI. “We are
grateful to our UK colleagues for their contribution, professionalism and dedication over
the years and we are committed to supporting them with this transition. We believe that
Particle Dynamics, with its strong expertise and growing international presence, is well
placed to build on the site’s capabilities and support its continued development.”

“Particle Dynamics' acquisition of EUROAPI UK Ltd is part of a strategic move to
strengthen our global particle engineering capabilities, and expand the market
segments we can serve,” said Nicolas Fortin, Chief Executive Officer of Particle
Dynamics. “We are committed to invest in the Haverhill site, with plans to add new
commercial-scale spray drying capabilities, and exceptional talents, as we extend our
high quality CDMO service offerings to pharmaceutical innovators.”

The transaction was completed under financial terms reflecting the fair value of the
shares sold1. It is expected to have a limited impact on EUROAPI’s H1 2025
consolidated financial statements. All operations and associated commitments related
to the company will be transferred to Particle Dynamics. The financial terms of the
transaction have not been disclosed. In 2024, net sales from the Haverhill site totalled
about 35 million euros, with nearly 80% attributed to Sanofi.


About EUROAPI
EUROAPI is focused on reinventing active ingredient solutions to sustainably meet customers’
and patients’ needs around the world. We are a leading player in active pharmaceutical
ingredients with approximately 200 products in our portfolio, offering a large span of
technologies while developing innovative molecules through our Contract Development and
Manufacturing Organization (CDMO) activities.


1Subject to potential additional effects related to identified items or subsequent accounting adjustments
as defined by the SPA.

1
Taking action for health by enabling access to essential therapies inspires our 3,430
employees every day. With strong research and development capabilities and six
manufacturing sites, all located in Europe, EUROAPI ensures API manufacturing of the highest
quality to supply customers in more than 80 countries. EUROAPI is listed on Euronext Paris
(ISIN: FR0014008VX5; ticker: EAPI). Find out more at www.euroapi.com and follow us on
LinkedIn.




Media Relations contact: Investor Relations contact:
Laurence Bollack Sophie Palliez-Capian
Tel.: +33 (0)6 81 86 80 19 Tel.: +33 (0)6 87 89 33 51
mr@euroapi.com Sophie.palliez@euroapi.com




Forward-Looking Statements
Certain information contained in this press release is forward looking and not historical data. These forward-looking
statements are based on opinions, projections and current assumptions including, but not limited to, assumptions
concerning the Group’s current and future strategy, financial and non-financial future results and the environment
in which the Group operates, as well as events, operations, future services or product development and potential.
Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Forward looking statements and information do not constitute
guarantees of future performances, and are subject to known or unknown risks, uncertainties and other factors, a
large number of which are difficult to predict and generally outside the control of the Group, which could cause
actual results, performances or achievements, or the results of the sector or other events, to differ materially from
those described or suggested by these forward-looking statements. These risks and uncertainties include those
that are indicated and detailed in Chapter 3 “Risk factors” of the Universal Registration Document filed with the
French Financial Markets Authority (Autorité des marchés financiers, AMF) on April 1, 2025. These forward-looking
statements are given only as of the date of this press release and the Group expressly declines any obligation or
commitment to publish updates or corrections of the forward-looking statements included in this press release in
order to reflect any change affecting the forecasts or events, conditions or circumstances on which these forward-
looking statements are based.




2